• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

用作肿瘤靶向磁共振成像造影剂的肽修饰超小超顺磁性氧化铁的制备与表征

Preparation and characterization of peptide modified ultrasmall superparamagnetic iron oxides used as tumor targeting MRI contrast agent.

作者信息

Yin Jie, Yin Guangfu, Pu Ximing, Huang Zhongbing, Yao Dajin

机构信息

College of Materials Science and Engineering, Sichuan University No. 24, South 1st Section, 1st Ring Road Chengdu 610065 PR China

School of Automation and Information Engineering, Sichuan University of Science and Engineering Zigong 643000 PR China.

出版信息

RSC Adv. 2019 Jun 20;9(34):19397-19407. doi: 10.1039/c9ra02636c. eCollection 2019 Jun 19.

DOI:10.1039/c9ra02636c
PMID:35519366
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9065400/
Abstract

As desirable contrast agents for magnetic resonance imaging (MRI), ultrasmall superparamagnetic iron oxides (USPIOs) are required to exhibit both low cytotoxicity and specific targetability besides superparamagnetism to achieve better imaging contrast at lower dose, and cladding with biocompatible polymers and modification with targeting ligands are considered to be the most effective strategies. In this study, novel dextran wrapped and peptide WSGPGVWGASVK (peptide-WSG) grafted USPIOs were meticulously prepared and systematically characterized. Firstly, dextran (Dex) cladded USPIOs (USPIOs@Dex) were synthesized with a well-designed co-precipitation procedure in which the biocompatible dextran played dual roles of grain inhibitor and cladding agent. After that, sodium citrate was applied to carboxylize the hydroxyls of the dextran molecules an esterification reaction, and then tumor targeting peptide-WSG was grafted to the carboxyl groups by the EDC method. The XRD, TEM, and FTIR results showed that inverse spinel structure FeO crystallites were nucleated and grown in aqueous solution, and the catenulate dextran molecules gradually bound on their surface, meanwhile the growth of grains was inhibited. The size of original crystallite grains was about 7 nm, but the mean size of USPIOs@Dex aggregates was 165.20 nm. After surface modification by sodium citrate and peptide-WSG with ultrasonic agitation, the size of the USPIOs@Dex-WSG aggregates was smaller (66.06 nm) because the hydrophilicity was improved, so USPIOs@Dex-WSG could evade being eliminated by RES more easily, and prolong residence time in blood circulation. The VSM and T-weighted MRI results showed that USPIOs@Dex-WSG were superparamagnetic with a saturation magnetization of 44.65 emu g, and with high transverse relaxivity as the relaxivity coefficient value was 229.70 mM s. The results of MTT assays and the Prussian blue staining revealed that USPIOs@Dex-WSG exhibited nontoxicity for normal cells such as L929 and HUVECs, and were specifically targeted to the SKOV-3 cells. Thus, the novel dextran wrapped and WSG-peptide grafted USPIOs have potential to be applied as tumor active targeting contrast agents for MRI.

摘要

作为磁共振成像(MRI)理想的造影剂,除了超顺磁性外,超小超顺磁性氧化铁(USPIOs)还需要表现出低细胞毒性和特异性靶向性,以便在较低剂量下实现更好的成像对比度,而用生物相容性聚合物包覆和用靶向配体修饰被认为是最有效的策略。在本研究中,精心制备并系统表征了新型葡聚糖包裹且肽WSGPGVWGASVK(肽-WSG)接枝的USPIOs。首先,采用精心设计的共沉淀法合成了葡聚糖(Dex)包覆的USPIOs(USPIOs@Dex),其中生物相容性葡聚糖起到了晶粒抑制剂和包覆剂的双重作用。之后,通过酯化反应使用柠檬酸钠将葡聚糖分子的羟基羧基化,然后通过EDC法将肿瘤靶向肽-WSG接枝到羧基上。XRD、TEM和FTIR结果表明,反尖晶石结构的FeO微晶在水溶液中形核并生长,链状葡聚糖分子逐渐结合在其表面,同时晶粒生长受到抑制。原始微晶颗粒的尺寸约为7nm,但USPIOs@Dex聚集体的平均尺寸为165.20nm。经柠檬酸钠和肽-WSG超声搅拌表面修饰后,USPIOs@Dex-WSG聚集体的尺寸更小(66.06nm),因为亲水性得到了改善,所以USPIOs@Dex-WSG能够更轻松地逃避被RES清除,并延长在血液循环中的停留时间。VSM和T加权MRI结果表明,USPIOs@Dex-WSG具有超顺磁性,饱和磁化强度为44.65emu g,横向弛豫率高,弛豫率系数值为229.70mM s。MTT试验和普鲁士蓝染色结果表明,USPIOs@Dex-WSG对L929和HUVECs等正常细胞无毒,且能特异性靶向SKOV-3细胞。因此,新型葡聚糖包裹且WSG-肽接枝的USPIOs有潜力作为MRI的肿瘤活性靶向造影剂应用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/848b/9065400/aa410f12f897/c9ra02636c-f14.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/848b/9065400/e67b5362865e/c9ra02636c-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/848b/9065400/5fa4ffc95cbd/c9ra02636c-f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/848b/9065400/6d2abe5b043a/c9ra02636c-f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/848b/9065400/6f98c25418f5/c9ra02636c-f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/848b/9065400/c134e6758ff0/c9ra02636c-f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/848b/9065400/a14aca391253/c9ra02636c-f6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/848b/9065400/f6e94ee77a0c/c9ra02636c-f7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/848b/9065400/7af525b2de38/c9ra02636c-f8.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/848b/9065400/f4b6a8c5247f/c9ra02636c-f9.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/848b/9065400/fe3187274cb5/c9ra02636c-f10.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/848b/9065400/cd4db51bf936/c9ra02636c-f11.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/848b/9065400/ec1a28fb9fea/c9ra02636c-f12.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/848b/9065400/a10fe16422d9/c9ra02636c-f13.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/848b/9065400/aa410f12f897/c9ra02636c-f14.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/848b/9065400/e67b5362865e/c9ra02636c-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/848b/9065400/5fa4ffc95cbd/c9ra02636c-f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/848b/9065400/6d2abe5b043a/c9ra02636c-f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/848b/9065400/6f98c25418f5/c9ra02636c-f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/848b/9065400/c134e6758ff0/c9ra02636c-f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/848b/9065400/a14aca391253/c9ra02636c-f6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/848b/9065400/f6e94ee77a0c/c9ra02636c-f7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/848b/9065400/7af525b2de38/c9ra02636c-f8.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/848b/9065400/f4b6a8c5247f/c9ra02636c-f9.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/848b/9065400/fe3187274cb5/c9ra02636c-f10.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/848b/9065400/cd4db51bf936/c9ra02636c-f11.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/848b/9065400/ec1a28fb9fea/c9ra02636c-f12.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/848b/9065400/a10fe16422d9/c9ra02636c-f13.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/848b/9065400/aa410f12f897/c9ra02636c-f14.jpg

相似文献

1
Preparation and characterization of peptide modified ultrasmall superparamagnetic iron oxides used as tumor targeting MRI contrast agent.用作肿瘤靶向磁共振成像造影剂的肽修饰超小超顺磁性氧化铁的制备与表征
RSC Adv. 2019 Jun 20;9(34):19397-19407. doi: 10.1039/c9ra02636c. eCollection 2019 Jun 19.
2
Peptide-Decorated Ultrasmall Superparamagnetic Nanoparticles as Active Targeting MRI Contrast Agents for Ovarian Tumors.肽修饰的超小超顺磁性纳米颗粒作为卵巢肿瘤主动靶向 MRI 对比剂。
ACS Appl Mater Interfaces. 2019 Nov 6;11(44):41038-41050. doi: 10.1021/acsami.9b14394. Epub 2019 Oct 25.
3
Specific targeting of breast tumor by octreotide-conjugated ultrasmall superparamagnetic iron oxide particles using a clinical 3.0-Tesla magnetic resonance scanner.使用临床3.0特斯拉磁共振扫描仪,通过奥曲肽偶联的超小超顺磁性氧化铁颗粒对乳腺肿瘤进行特异性靶向。
Acta Radiol. 2009 Jul;50(6):583-94. doi: 10.1080/02841850902902557.
4
Ultrasmall superparamagnetic iron oxide (USPIO)-based liposomes as magnetic resonance imaging probes.基于超顺磁性氧化铁(USPIO)的脂质体作为磁共振成像探针。
Int J Nanomedicine. 2012;7:2349-59. doi: 10.2147/IJN.S30617. Epub 2012 May 9.
5
Biomimetic Mineralization of Tumor Targeted Ferromagnetic Iron Oxide Nanoparticles Used for Media of Magnetic Hyperthermia.用于磁热疗介质的肿瘤靶向性铁磁性氧化铁纳米颗粒的仿生矿化
Curr Drug Deliv. 2017;14(3):349-356. doi: 10.2174/1567201813666160324155724.
6
Bisphosphonate-anchored PEGylation and radiolabeling of superparamagnetic iron oxide: long-circulating nanoparticles for in vivo multimodal (T1 MRI-SPECT) imaging.双膦酸盐锚定聚乙二醇化和超顺磁性氧化铁的放射性标记:用于体内多模态(T1 MRI-SPECT)成像的长循环纳米颗粒。
ACS Nano. 2013 Jan 22;7(1):500-12. doi: 10.1021/nn3046055. Epub 2012 Dec 10.
7
A MSLN-targeted multifunctional nanoimmunoliposome for MRI and targeting therapy in pancreatic cancer.一种针对 MSLN 的多功能纳米免疫脂质体,用于胰腺癌的 MRI 靶向治疗。
Int J Nanomedicine. 2012;7:5053-65. doi: 10.2147/IJN.S34801. Epub 2012 Sep 19.
8
Evaluating size-dependent relaxivity of PEGylated-USPIOs to develop gadolinium-free T1 contrast agents for vascular imaging.评估 PEGylated-USPIO 的尺寸依赖性弛豫率,以开发用于血管成像的无钆 T1 对比剂。
J Biomed Mater Res A. 2018 Sep;106(9):2440-2447. doi: 10.1002/jbm.a.36438.
9
[Construction of RGD10-NGR9 dual-targeting superparamagnetic iron oxide and its magnetic resonance imaging features in nude mice].[RGD10-NGR9双靶点超顺磁性氧化铁的构建及其在裸鼠体内的磁共振成像特征]
Zhonghua Zhong Liu Za Zhi. 2013 Nov;35(11):808-13.
10
Novel peptide targeting integrin αvβ3-rich tumor cells by magnetic resonance imaging.新型靶向整合素αvβ3 高表达肿瘤细胞的磁共振成像肽。
J Magn Reson Imaging. 2011 Aug;34(2):395-402. doi: 10.1002/jmri.22620.

引用本文的文献

1
FROP-1 peptide-conjugated ultrasmall superparamagnetic nanoparticles as a targeted T1-weighted MR contrast agent for breast cancer: in vitro study.FROP-1肽偶联的超小超顺磁性纳米颗粒作为乳腺癌的靶向T1加权磁共振造影剂:体外研究
BMC Biomed Eng. 2025 May 1;7(1):5. doi: 10.1186/s42490-025-00091-7.
2
Specific nanoprobe design for MRI: Targeting laminin in the blood-brain barrier to follow alteration due to neuroinflammation.特定的 MRI 纳米探针设计:靶向血脑屏障中的层粘连蛋白,以跟踪神经炎症引起的变化。
PLoS One. 2024 Apr 11;19(4):e0302031. doi: 10.1371/journal.pone.0302031. eCollection 2024.
3
Recent Advances of Bioresponsive Nano-Sized Contrast Agents for Ultra-High-Field Magnetic Resonance Imaging.

本文引用的文献

1
Multifunctional hybrid nanoconstruct of zerovalent iron and carbon dots for magnetic resonance angiography and optical imaging: An In vivo study.多功能零价铁和碳点杂化纳米构建体用于磁共振血管造影和光学成像:体内研究。
Biomaterials. 2018 Jul;171:46-56. doi: 10.1016/j.biomaterials.2018.04.012. Epub 2018 Apr 10.
2
Nano-confinement-driven enhanced magnetic relaxivity of SPIONs for targeted tumor bioimaging.纳米限域增强 SPIONs 的磁弛豫率用于靶向肿瘤生物成像。
Nanoscale. 2017 Dec 21;10(1):284-294. doi: 10.1039/c7nr07035g.
3
FeO nanoparticles modified by CD-containing star polymer for MRI and drug delivery.
用于超高场磁共振成像的生物响应性纳米级造影剂的最新进展
Front Chem. 2020 Mar 20;8:203. doi: 10.3389/fchem.2020.00203. eCollection 2020.
载有半胱氨酸的星型聚合物修饰的 FeO 纳米颗粒用于 MRI 和药物递送。
Colloids Surf B Biointerfaces. 2017 Oct 1;158:213-221. doi: 10.1016/j.colsurfb.2017.06.049. Epub 2017 Jun 30.
4
Functionalized graphene oxide/FeO hybrids for cellular magnetic resonance imaging and fluorescence labeling.用于细胞磁共振成像和荧光标记的功能化氧化石墨烯/氧化亚铁杂化物
Mater Sci Eng C Mater Biol Appl. 2017 Sep 1;78:817-825. doi: 10.1016/j.msec.2017.04.139. Epub 2017 Apr 23.
5
Design and characterization of lisinopril-loaded superparamagnetic nanoparticles as a new contrast agent for in vitro, in vivo MRI imaging, diagnose the tumors and drug delivery system.负载赖诺普利的超顺磁性纳米颗粒的设计与表征:一种用于体外、体内磁共振成像、肿瘤诊断及药物递送系统的新型造影剂
J Mater Sci Mater Med. 2017 Jun;28(6):91. doi: 10.1007/s10856-017-5900-0. Epub 2017 May 11.
6
Molecular imaging of activated platelets via antibody-targeted ultra-small iron oxide nanoparticles displaying unique dual MRI contrast.通过抗体靶向超小氧化铁纳米颗粒对活化血小板进行分子成像,显示出独特的双重 MRI 对比。
Biomaterials. 2017 Jul;134:31-42. doi: 10.1016/j.biomaterials.2017.04.037. Epub 2017 Apr 22.
7
Active targeting theranostic iron oxide nanoparticles for MRI and magnetic resonance-guided focused ultrasound ablation of lung cancer.用于肺癌磁共振成像及磁共振引导聚焦超声消融的主动靶向诊疗一体化氧化铁纳米颗粒
Biomaterials. 2017 May;127:25-35. doi: 10.1016/j.biomaterials.2017.02.037. Epub 2017 Mar 1.
8
Functionalized magnetic nanochains with enhanced MR imaging: A novel nanosystem for targeting and inhibition of early glioma.具有增强磁共振成像功能的功能化磁性纳米链:一种用于靶向和抑制早期胶质瘤的新型纳米系统。
Colloids Surf B Biointerfaces. 2016 Apr 1;140:437-445. doi: 10.1016/j.colsurfb.2016.01.006. Epub 2016 Jan 6.
9
Multifunctional nano manganese ferrite ferrofluid for efficient theranostic application.用于高效诊疗应用的多功能纳米锰铁氧体铁磁流体
Colloids Surf B Biointerfaces. 2015 Dec 1;136:1089-97. doi: 10.1016/j.colsurfb.2015.11.010. Epub 2015 Nov 10.
10
Conjugation of iron oxide nanoparticles with RGD-modified dendrimers for targeted tumor MR imaging.用于靶向肿瘤磁共振成像的氧化铁纳米颗粒与RGD修饰树枝状大分子的共轭
ACS Appl Mater Interfaces. 2015 Mar 11;7(9):5420-8. doi: 10.1021/am508983n. Epub 2015 Feb 26.